WebJul 3, 2015 · The objective of this study was to determine the efficacy of a novel, highly potent, orally-bioavailable c-MET inhibitor, INC280, in blocking cell phenotypes important in ovarian cancer metastasis. Using in vitro and ex vivo models, we demonstrate that INC280 inhibits HGF-induced c-MET, and reduces downstream signalling. Web研究证明。 MET 14外显子跳跃突变是非小细胞肺癌(NSCLC)的驱动基因,因此2024年5月当美国FDA批准的首个靶向MET 14外显子跳跃突变的药物卡马替尼(TABRECTA,INC280)获批上市后,收到医药界及非小细胞癌患者的广泛关注。
Capmatinib(INC280、卡马替尼)_肺癌_抗癌药物_全球肿瘤医生网
WebMay 26, 2024 · 9004 Background: Capmatinib is a highly potent and selective MET inhibitor. Previous data of GEOMETRY mono-1 study showed a clinically meaningful overall response rate (ORR) and manageable toxicity profile in patients (pts) with METΔex14–mutated NSCLC who received 1–2 prior lines of treatment (tx) (Cohort 4) and in particular a high ORR in tx … Web仅限科研使用. Capmatinib (INCB28060, INC280, NVP-INC280)是一种新型的,ATP竞争性 c-MET 抑制剂,无细胞试验中 IC50 为0.13 nM,对RONβ,EGFR和HER-3无活性。. … reading and writing strings in c
卡马替尼(INC280)的临床研究数据-康安途海外医疗
WebMar 11, 2024 · INC280 treatment inhibits growth of a c-MET-amplified MKN45 (RUNX3-positive) and SNU620 (RUNX3-negative) diffuse type cells. Then, INC280 showed the … WebJun 10, 2024 · 因此,2010年我们提出了第一个研究思路,考虑可以把c-met抑制剂inc280和吉非替尼两药联合起来以克服耐药。 在此思路下,我们开始了一系列临床I期、II期研究,就是非常有名的INC280联合吉非替治疗c-MET扩增肺癌患者的有效性及安全性研究。 WebJul 3, 2015 · The persistent inhibitory effect of INC280, is consistent with studies reported by Liu et al., who demonstrated that a single dose of INC280 in vivo resulted in 90% inhibition of c-MET ... reading and writing synonym